Learn About Familial Atypical Multiple Mole Melanoma Syndrome

Who are the top Familial Atypical Multiple Mole Melanoma Syndrome Local Doctors?
Elite
Elite
 
 
 
 
Learn about our expert tiers
Learn more
Elite
What are the latest Familial Atypical Multiple Mole Melanoma Syndrome Clinical Trials?
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
Summary: This study will investigate how genetic and environmental factors contribute to the development of melanoma, a type of skin cancer, and related conditions.~Individuals >= 2 years with a personal or family history of melanoma or atypical spitzoid/Spitz tumor may be eligible for this study. Participants will:~Fill out one or two questionnaires about their personal and family medical history.~Provide...
Match to trials
Find the right clinical trials for you in under a minute
Get started
Italian Registry of Families At Risk of Pancreatic Cancer
Summary: IRFARPC is a multicenter national registry designed to study the diagnosis and predisposing factors of subjects with an inherited increased risk for pancreatic cancer.
Who are the sources who wrote this article ?

Published Date: May 10, 2022
Published By: Genetic and Rare Diseases Informnation Center

What are the Latest Advances for Familial Atypical Multiple Mole Melanoma Syndrome?
Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post-marketing surveillance.
Summary: Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post-marketing surveillance.
Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma.
Summary: Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma.
Tired of the same old research?
Check Latest Advances
An Update of Cutaneous Melanoma Patients Treated in Adjuvancy With the Allogeneic Melanoma Vaccine VACCIMEL and Presentation of a Selected Case Report With In-Transit Metastases.
Summary: An Update of Cutaneous Melanoma Patients Treated in Adjuvancy With the Allogeneic Melanoma Vaccine VACCIMEL and Presentation of a Selected Case Report With In-Transit Metastases.